Radford G, Vrbanac L, de Nys R, Worthley D, Wright J, Hasty J
Cancers (Basel). 2024; 16(17).
PMID: 39272829
PMC: 11394440.
DOI: 10.3390/cancers16172971.
Geervliet M, de Vries H, Jansen C, Rutten V, van Hees H, Wen C
Front Microbiol. 2022; 13:842437.
PMID: 35283814
PMC: 8914288.
DOI: 10.3389/fmicb.2022.842437.
Schroder N, Korsa A, Wami H, Mantel O, Dobrindt U, Kurtz J
Evol Med Public Health. 2022; 10(1):71-86.
PMID: 35186295
PMC: 8853844.
DOI: 10.1093/emph/eoac001.
Park K, Park S, Nagappan A, Ray N, Kim J, Yoon S
Nutrients. 2021; 13(3).
PMID: 33804493
PMC: 8000835.
DOI: 10.3390/nu13030811.
Nakkarach A, Foo H, Song A, Abdul Mutalib N, Nitisinprasert S, Withayagiat U
Microb Cell Fact. 2021; 20(1):36.
PMID: 33546705
PMC: 7863513.
DOI: 10.1186/s12934-020-01477-z.
Chemical structure and genetic organization of the E. coli O6:K15 capsular polysaccharide.
Azurmendi H, Veeramachineni V, Freese S, Lichaa F, Freedberg D, Vann W
Sci Rep. 2020; 10(1):12608.
PMID: 32724125
PMC: 7387560.
DOI: 10.1038/s41598-020-69476-z.
Promising discovery of beneficial in the human gut.
Nakkarach A, Foo H, Song A, Nitisinprasert S, Withayagiat U
3 Biotech. 2020; 10(7):296.
PMID: 32550113
PMC: 7283410.
DOI: 10.1007/s13205-020-02289-z.
Worm-Based Alternate Assessment of Probiotic Intervention against Gut Barrier Infection.
Kim J, Moon Y
Nutrients. 2019; 11(9).
PMID: 31500368
PMC: 6770392.
DOI: 10.3390/nu11092146.
Nononcogenic restoration of the intestinal barrier by E. coli-delivered human EGF.
Yu M, Kim J, Ahn J, Moon Y
JCI Insight. 2019; 4(16).
PMID: 31434808
PMC: 6777819.
DOI: 10.1172/jci.insight.125166.
Prophylaxis of acute respiratory infections via improving the immune system in late preterm newborns with . strain Nissle 1917: a controlled pilot trial.
Aryayev M, Senkivska L, Bredeleva N, Talashova I
Pilot Feasibility Stud. 2018; 4:79.
PMID: 29713493
PMC: 5911946.
DOI: 10.1186/s40814-018-0271-y.
Escherichia coli EDL933 requires gluconeogenic nutrients to successfully colonize the intestines of streptomycin-treated mice precolonized with E. coli Nissle 1917.
Schinner S, Mokszycki M, Adediran J, Leatham-Jensen M, Conway T, Cohen P
Infect Immun. 2015; 83(5):1983-91.
PMID: 25733524
PMC: 4399065.
DOI: 10.1128/IAI.02943-14.
Role of F1C fimbriae, flagella, and secreted bacterial components in the inhibitory effect of probiotic Escherichia coli Nissle 1917 on atypical enteropathogenic E. coli infection.
Kleta S, Nordhoff M, Tedin K, Wieler L, Kolenda R, Oswald S
Infect Immun. 2014; 82(5):1801-12.
PMID: 24549324
PMC: 3993448.
DOI: 10.1128/IAI.01431-13.
An Escherichia coli Nissle 1917 missense mutant colonizes the streptomycin-treated mouse intestine better than the wild type but is not a better probiotic.
Adediran J, Leatham-Jensen M, Mokszycki M, Frimodt-Moller J, Krogfelt K, Kazmierczak K
Infect Immun. 2014; 82(2):670-82.
PMID: 24478082
PMC: 3911375.
DOI: 10.1128/IAI.01149-13.
Impact of metal ion homeostasis of genetically modified Escherichia coli Nissle 1917 and K12 (W3110) strains on colonization properties in the murine intestinal tract.
Kupz A, Fischer A, Nies D, Grass G, Gobel U, Bereswill S
Eur J Microbiol Immunol (Bp). 2013; 3(3):229-35.
PMID: 24265943
PMC: 3832094.
DOI: 10.1556/EuJMI.3.2013.3.12.
Pro-inflammatory potential of Escherichia coli strains K12 and Nissle 1917 in a murine model of acute ileitis.
Bereswill S, Fischer A, Dunay I, Kuhl A, Gobel U, Liesenfeld O
Eur J Microbiol Immunol (Bp). 2013; 3(2):126-34.
PMID: 24265929
PMC: 3832091.
DOI: 10.1556/EuJMI.3.2013.2.6.
Probiotics: properties, examples, and specific applications.
Behnsen J, Deriu E, Sassone-Corsi M, Raffatellu M
Cold Spring Harb Perspect Med. 2013; 3(3):a010074.
PMID: 23457295
PMC: 3579206.
DOI: 10.1101/cshperspect.a010074.
A multivalent adsorption apparatus explains the broad host range of phage phi92: a comprehensive genomic and structural analysis.
Schwarzer D, Buettner F, Browning C, Nazarov S, Rabsch W, Bethe A
J Virol. 2012; 86(19):10384-98.
PMID: 22787233
PMC: 3457257.
DOI: 10.1128/JVI.00801-12.
Enhanced wound healing by recombinant Escherichia coli Nissle 1917 via human epidermal growth factor receptor in human intestinal epithelial cells: therapeutic implication using recombinant probiotics.
Choi H, Ahn J, Park S, Do K, Kim J, Moon Y
Infect Immun. 2011; 80(3):1079-87.
PMID: 22184415
PMC: 3294649.
DOI: 10.1128/IAI.05820-11.
Myristoylation negative msbB-mutants of probiotic E. coli Nissle 1917 retain tumor specific colonization properties but show less side effects in immunocompetent mice.
Stritzker J, Hill P, Gentschev I, Szalay A
Bioeng Bugs. 2011; 1(2):139-45.
PMID: 21326939
PMC: 3026454.
DOI: 10.4161/bbug.1.2.10286.
Safety of probiotic Escherichia coli strain Nissle 1917 depends on intestinal microbiota and adaptive immunity of the host.
Gronbach K, Eberle U, Muller M, Olschlager T, Dobrindt U, Leithauser F
Infect Immun. 2010; 78(7):3036-46.
PMID: 20421387
PMC: 2897399.
DOI: 10.1128/IAI.00218-10.